Expression profiling of blood samples from an SU5416 phase III metastatic colorectal cancer clinical trial: A novel strategy for biomarker identification

92Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

Abstract

Background: Microarray-based gene expression profiling is a powerful approach for the identification of molecular biomarkers of disease, particularly in human cancers. Utility of this approach to measure responses to therapy is less well established, in part due to challenges in obtaining serial biopsies. Identification of suitable surrogate tissues will help minimize limitations imposed by those challenges. This study describes an approach used to identify gene expression changes that might serve as surrogate biomarkers of drug activity. Methods: Expression profiling using microarrays was applied to peripheral blood mononuclear cell (PBMC) samples obtained from patients with advanced colorectal cancer participating in a Phase III clinical trial. The PBMC samples were harvested pre-treatment and at the end of the first 6-week cycle from patients receiving standard of care chemotherapy or standard of care plus SU5416, a vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor. Results from matched pairs of PBMC samples from 23 patients were queried for expression changes that consistently correlated with SU5416 administration. Results: Thirteen transcripts met this selection criterion; six were further tested by quantitative RT-PCR analysis of 62 additional samples from this trial and a second SU5416 Phase III trial of similar design. This method confirmed four of these transcripts (CD24, lactoferrin, lipocalin 2, and MMP-9) as potential biomarkers of drug treatment. Discriminant analysis showed that expression profiles of these 4 transcripts could be used to classify patients by treatment arm in a predictive fashion. Conclusions: These results establish a foundation for the further exploration of peripheral blood cells as a surrogate system for biomarker analyses in clinical oncology studies. © 2003 DePrimo et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

DePrimo, S. E., Wong, L. M., Khatry, D. B., Nicholas, S. L., Manning, W. C., Smolich, B. D., … Cherrington, J. M. (2003). Expression profiling of blood samples from an SU5416 phase III metastatic colorectal cancer clinical trial: A novel strategy for biomarker identification. BMC Cancer, 3. https://doi.org/10.1186/1471-2407-3-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free